DRUG · Mapped RxNorm record
omalizumab
Normalized identity: omalizumab View linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab
NCT00287378
Study summary
ClinicalTrials.govEffect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab
Design: INTERVENTIONAL · Status: TERMINATED · Phase: NA
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Advertisement
Conditions
Asthmaverified · MONDO: asthma
Allergyverified · MONDO: allergic disease
Interventions
omalizumabDRUG · verified · RxNorm: omalizumab
Sponsors & collaborators
University of North Carolina, Chapel Hilllead sponsor
National Institutes of Health (NIH)collaborator
Genentech, Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00287378 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.